Want to see AU:GSS full AI Analyst Report?

Genetic Signatures Ltd. (GSS) Price & Analysis

8 Followers

GSS Stock Chart & Stats

AU$0.24

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.24

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.05 - AU$0.43

Previous CloseN/A

Volume34.30K

Average Volume (3M)149.45K

Market Cap

AU$13.40M

Enterprise ValueAU$27.47

Total Cash (Recent Filing)AU$29.87M

Total Debt (Recent Filing)AU$653.00K

Price to Earnings (P/E)―

Beta0.72

Next Earnings

Aug 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding227,138,820

10 Day Avg. Volume161,537

30 Day Avg. Volume149,454

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)1.65

Price to Sales (P/S)5.20

P/FCF Ratio-6.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.05

Revenue Forecast (FY)AU$21.80M

Bulls Say, Bears Say

Bulls Say

Proprietary PlatformGSS's proprietary 3base® platform underpins its multiplex PCR assays for gastrointestinal, respiratory and other pathogen detection. Platform-based technology supports efficient new assay development, product breadth and differentiation that can drive durable clinical adoption and partner interest.

Consumable Recurring RevenueThe business model centers on consumable assay sales that generate repeat purchases tied to test volumes. This attach-rate creates a predictable, recurring revenue stream and scale potential as diagnostic volumes grow, supporting longer-term revenue stability versus one-time sales.

Low Financial LeverageA very low debt-to-equity ratio preserves financial flexibility and reduces solvency risk. Minimal leverage lowers interest burden and gives management room to allocate capital toward R&D, manufacturing scale-up or distribution partnerships without immediate refinancing pressure.

Bears Say

Sustained UnprofitabilityPersistent negative net profit and EBIT/EBITDA margins signal the company is not currently generating operating profits. Over a multi-month horizon this limits internal funding for growth initiatives, increases reliance on external capital and heightens execution risk for margin improvement.

Negative Operating & Free Cash FlowNegative operating and free cash flows show core operations consume cash rather than generate it. Weak cash generation constrains the ability to scale production or commercialization, increases funding needs, and makes strategic initiatives dependent on external financing over the next several months.

Negative Return On EquityA negative return on equity indicates the company is not converting invested capital into shareholder returns. This structural weakness can deter long-term investors, limit access to favorable financing and puts pressure on management to materially improve profitability or secure new revenue channels.

Genetic Signatures Ltd. News

Genetic Signatures Cuts Costs, Secures Danish Deal and Resets Global Growth Strategy

Genetic Signatures Ltd. ( ($AU:GSS) ) has provided an update. Genetic Signatures has completed an organisational restructuring that...

11d ago

GSS

Genetic Signatures plays down BCAL stake, stresses business as usual

Genetic Signatures Ltd. ( ($AU:GSS) ) has shared an update. Genetic Signatures has responded to BCAL Diagnostics’ announcement...

1M ago

GSS

BCAL buys 10.2% stake in Genetic Signatures to broaden diagnostics platform

Genetic Signatures Ltd. ( ($AU:GSS) ) has issued an announcement. BCAL Diagnostics, an Australian healthcare company focused on...

1M ago

GSS

Genetic Signatures Outlines 90-Day Strategic Review Under Strict Investor Disclaimers

An update from Genetic Signatures Ltd. ( ($AU:GSS) ) is now available. Genetic Signatures Ltd. has released an...

2M ago

GSS

Genetic Signatures Unveils Post-Review Strategy Ahead of Investor Webinar

Genetic Signatures Ltd. ( ($AU:GSS) ) has provided an update. Genetic Signatures will host an investor webinar on...

2M ago

GSS

Genetic Signatures Announces Departure of Director Neil Gunn

An update from Genetic Signatures Ltd. ( ($AU:GSS) ) is now available. Genetic Signatures Limited has announced that...

3M ago

GSS

Genetic Signatures Reshapes Board to Support Leaner Strategy

Genetic Signatures Ltd. ( ($AU:GSS) ) just unveiled an update. Genetic Signatures Limited has reorganised its board to...

3M ago

GSS

Genetic Signatures Quantifies Revenue Impact of Danish Supply Deal

Genetic Signatures Ltd. ( ($AU:GSS) ) has provided an announcement. Genetic Signatures has detailed the expected impact of...

4M ago

GSS

Genetic Signatures Sets Growth Path in Molecular Diagnostics for 1H FY26

Genetic Signatures Ltd. ( ($AU:GSS) ) has provided an announcement. Genetic Signatures Ltd., an ASX-listed molecular diagnostics firm...

5M ago

GSS

Genetic Signatures Options Lapse, Simplifying Capital Structure

Genetic Signatures Ltd. ( ($AU:GSS) ) has issued an announcement. Genetic Signatures Limited has notified the market of...

6M ago

GSS

GSS FAQ

What was Genetic Signatures Ltd.’s price range in the past 12 months?

Genetic Signatures Ltd. lowest share price was AU$0.05 and its highest was AU$0.43 in the past 12 months.

What is Genetic Signatures Ltd.’s market cap?

Genetic Signatures Ltd.’s market cap is AU$13.40M.

When is Genetic Signatures Ltd.’s upcoming earnings report date?

Genetic Signatures Ltd.’s upcoming earnings report date is Aug 24, 2026 which is in 22 days.

How were Genetic Signatures Ltd.’s earnings last quarter?

Genetic Signatures Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.028 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Genetic Signatures Ltd. overvalued?

According to Wall Street analysts Genetic Signatures Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Genetic Signatures Ltd. pay dividends?

Genetic Signatures Ltd. does not currently pay dividends.

What is Genetic Signatures Ltd.’s EPS estimate?

Genetic Signatures Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Genetic Signatures Ltd. have?

Genetic Signatures Ltd. has 227,138,820 shares outstanding.

What happened to Genetic Signatures Ltd.’s price movement after its last earnings report?

Genetic Signatures Ltd. reported an EPS of -AU$0.028 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.043%.

Which hedge fund is a major shareholder of Genetic Signatures Ltd.?

Currently, no hedge funds are holding shares in AU:GSS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Genetic Signatures Ltd. Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-16.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Genetic Signatures Ltd.

Genetic Signatures Limited operates as a molecular diagnostics (MDx) enterprise, extending its reach across Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. The company engineers and manufactures an array of real-time Polymerase Chain Reaction (PCR)-based products, sold under the EasyScreen brand, for the identification of infectious diseases. Moreover, it offers its proprietary MDx 3Base platform technology, enabling hospitals and pathology laboratories to conduct comprehensive screenings for diverse infectious pathogens. Its offerings also encompass detection kits tailored for conditions such as gastrointestinal ailments, respiratory illnesses, sexual health concerns, antimicrobial resistance, meningitis, and tropical diseases. Founded in 2001, the firm is headquartered in Newtown, Australia.